Peregrine Doses First Patient in Brain Cancer Trial
Posted on: Friday, 3 August 2007, 12:20 CDT
Peregrine Pharmaceuticals says the first patient has been administered Cotara in a new clinical trial designed to evaluate the drug for the treatment of glioblastoma multiforme, a deadly form of brain cancer.
This multi-center open label Phase II safety and efficacy study is designed to enroll up to 40 glioblastoma patients who have experienced a first relapse. The study's primary objective is to confirm the maximum tolerated dose of Cotara in these GBM patients.
Secondary objectives include estimates of overall patient survival, progression free survival and the proportion of patients alive at six months.
Patients in the trial are receiving a single infusion of Cotara by convection-enhanced delivery (CED), an NIH-developed technique which delivers the agent to the tumor achieving up to a 10,000-fold greater concentration in local therapy exposure than conventional intravenous drug administration, while minimizing unwanted exposure to healthy tissue, according to Peregrine. This delivery method is expected to further enhance the tumor-killing potential of Cotara.
Source: Datamonitor
Related Articles
- Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer
- Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
- Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients
- Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
- Peregrine Reports Positive Data From Cotara Brain Cancer Trials
- Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
- Medical University of South Carolina Initiates New Trial of Cotara(R) in Brain Cancer Patients
- Peregrine Pharmaceuticals Initiates Patient Enrollment In New Cotara(R) Brain Cancer Trial
- Peregrine Pharmaceuticals Opens Patient Enrollment for Its Tarvacin(TM) Phase I Solid Cancer Therapy Clinical Trial
 |
 |
User Comments (0)
RSS Feeds